Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on IDEXX Laboratories, Inc..
We currently have 65 research reports from 3
Companies: Aptamer Group Plc
Companies: Futura Medical plc
Despite continued strong revenue growth from the existing Point-of-Care and Life Sciences activities, it is now apparent the new capacity expansion programme for enzymes fermentation will not contribute to revenues this year. As a result, management is now guiding to FY23 group revenues of ~£53m and Adj EBITDA of ~£10m, both around £4m lower than previous expectations. We update our forecasts accordingly and expect more information around the shape of the revenue ramp up in FY24 at the upcoming
Companies: EKF Diagnostics Holdings plc
Singer Capital Markets
Companies: Destiny Pharma Plc
Companies: Hvivo (HVO:LON)hVIVO plc (HVO:LON)
POLB announced today announces that the opposition to one of its European patents (Immunomodulator I) that was filed by a third party is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. POLB had previously disclosed in September 2021 that the Immunomodulator I European patent had been opposed but this has now been resolved. We maintain our BUY recommendation and 21p PT.
Companies: Poolbeg Pharma PLC
4th September 2023
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj
Companies: TXG LEX TXG CTL AGL SAR TSTL PYC TRR AREC
14th September 2023
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob
Companies: MKA CHH PMP LOOP KEYS CUSN AREC CUSN
Belluscura has reported interims in line with our expectations and notes strong momentum across its product range, particularly the DISCOV-R, and ‘transformational' progress in its global roll-out after signing Agreements with InnoMax and McKessen.
Companies: Belluscura PLC
Companies: Warpaint London PLC
Destiny Pharma’s H1 2023 interim results provided an overview of what has been a busy period of positive activity for the company. The group strengthened its balance sheet through the completion of an equity fundraise, generating £7.3m in gross proceeds, ending the period with a net cash position of £9.8m. Management has guided that the current cash reserves provide an operating cash runway into Q1 2025. In our view, given the currently turbulent biotech financing environment, the successful rai
Companies: TIDE IQG TND DEST JNEO
Artificial intelligence (AI) continues to accelerate at full speed, first by imitating the workings of a human brain and now it is drawing concepts of evolution, sometimes with synthetic data, artificially manufactured for training purposes or for privacy protection, and sometimes not even with human intervention. In this note, we examine how AI is being developed and applied by the NHS and UK mid/small cap companies for the benefit of human health and wellbeing.
AI in drug discovery and devel
Companies: FDBK AGY ETX DXSP HVO COG HVO PYC IXI IUG C4XD NSCI 8091
Creo Medical has reported its results for the 6 months to June 2023. As pre the recent trading update, revenues in the period were £15.7m, supported by growth from the Core Creo products and Endotherapy consumables. Gross profit increased, though gross margin declined marginally due to revenue mix. Creo’s cost base continues to fall supporting reduced operating losses. Cash at period end was £26.5m with £4.5m of R&D tax credits received post-period. The company expects to maintain its growth tra
Companies: Creo Medical Group Plc